Biogen Inc [BIIB] stock is trading at $124.99, down -2.88%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The BIIB shares have lost -6.87% over the last week, with a monthly amount drifted -1.24%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Biogen Inc [NASDAQ: BIIB] stock has seen the most recent analyst activity on April 28, 2025, when HSBC Securities downgraded its rating to a Hold but kept the price target unchanged to $118 for it. Previously, Argus downgraded its rating to Hold on April 04, 2025. On February 11, 2025, Bernstein initiated with a Mkt Perform rating and assigned a price target of $160 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $138 on January 02, 2025. BMO Capital Markets downgraded its rating to a Market Perform and reduced its price target to $164 on December 20, 2024. Stifel downgraded its rating to Hold for this stock on December 16, 2024, but kept the price target unchanged to $175.
Biogen Inc [BIIB] stock has fluctuated between $110.04 and $236.48 over the past year. Currently, Wall Street analysts expect the stock to reach $197.88 within the next 12 months. Biogen Inc [NASDAQ: BIIB] shares were valued at $124.99 at the most recent close of the market. An investor can expect a potential return of 58.32% based on the average BIIB price forecast.
Analyzing the BIIB fundamentals
Biogen Inc [NASDAQ:BIIB] reported sales of 9.40B for the trailing twelve months, which represents a growth of 6.17%. Gross Profit Margin for this corporation currently stands at 0.76% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.18%, and Net Profit Margin reading is 0.15%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.09 and Total Capital is 0.1. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.39.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 123.25 points at the first support level, and at 121.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 128.15, and for the 2nd resistance point, it is at 131.32.
Ratios To Look Out For
For context, Biogen Inc’s Current Ratio is 1.44. Also, the Quick Ratio is 1.01, while the Cash Ratio stands at 0.49. Considering the valuation of this stock, the price to sales ratio is 1.95, the price to book ratio is 1.08 and price to earnings (TTM) ratio is 12.34.
Transactions by insiders
Recent insider trading involved Izzar Rachid, Head of Global Product Strat., that happened on Jul 08 ’25 when 2223.0 shares were sold. Officer, Izzar Rachid completed a deal on Jul 08 ’25 to buy 2223.0 shares. Meanwhile, Head of Development Singhal Priya sold 3806.0 shares on May 19 ’25.
